Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04281498
Title Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Michal Bar-Natan
Indications

myelofibrosis

myeloproliferative neoplasm

Therapies

Enasidenib + Ruxolitinib

Age Groups: adult | senior
Covered Countries USA | CAN

Additional content available in CKB BOOST